tradingkey.logo

PharmaCyte Biotech Inc

PMCB
查看詳細走勢圖
0.765USD
-0.005-0.68%
收盤 12/24, 13:00美東報價延遲15分鐘
5.20M總市值
虧損本益比TTM

PharmaCyte Biotech Inc

0.765
-0.005-0.68%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-0.68%

5天

-7.25%

1月

+17.69%

6月

-27.83%

今年開始到現在

-51.27%

1年

-52.19%

查看詳細走勢圖

TradingKey PharmaCyte Biotech Inc股票評分

單位: USD 更新時間: 2025-12-24

操作建議

PharmaCyte Biotech Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名218/404位。機構持股佔比非常高,中期看,股價處於下降通道。近一個月,市場表現較差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

PharmaCyte Biotech Inc評分

相關信息

行業排名
218 / 404
全市場排名
410 / 4562
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 0 分析師
--
評級
--
目標均價
--
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

PharmaCyte Biotech Inc亮點

亮點風險
PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
業績轉盈
公司業績轉盈,最新年度盈利美元
估值合理
公司最新PE估值-0.69,處於3年歷史合理位
機構減倉
最新機構持股457.38K股,環比減少56.94%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉80.00K股
活躍度增加
近期活躍度增加,過去20天平均換手率4.02

PharmaCyte Biotech Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

PharmaCyte Biotech Inc簡介

PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
公司代碼PMCB
公司PharmaCyte Biotech Inc
CEOSilverman (Joshua N)
網址https://pharmacyte.com/

常見問題

PharmaCyte Biotech Inc(PMCB)的當前股價是多少?

PharmaCyte Biotech Inc(PMCB)的當前股價是 0.765。

PharmaCyte Biotech Inc 的股票代碼是什麼?

PharmaCyte Biotech Inc的股票代碼是PMCB。

PharmaCyte Biotech Inc股票的52週最高點是多少?

PharmaCyte Biotech Inc股票的52週最高點是1.900。

PharmaCyte Biotech Inc股票的52週最低點是多少?

PharmaCyte Biotech Inc股票的52週最低點是0.630。

PharmaCyte Biotech Inc的市值是多少?

PharmaCyte Biotech Inc的市值是5.20M。

PharmaCyte Biotech Inc的淨利潤是多少?

PharmaCyte Biotech Inc的淨利潤為23.36M。

現在PharmaCyte Biotech Inc(PMCB)的股票是買入、持有還是賣出?

根據分析師評級,PharmaCyte Biotech Inc(PMCB)的總體評級為--,目標價格為--。

PharmaCyte Biotech Inc(PMCB)股票的每股收益(EPS TTM)是多少

PharmaCyte Biotech Inc(PMCB)股票的每股收益(EPS TTM)是-1.116。
KeyAI